Hooman Mirzakhani, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Pre-Eclampsia | 13 | 2023 | 1200 | 4.170 |
Why?
|
Asthma | 25 | 2024 | 6011 | 2.900 |
Why?
|
Vitamin D | 24 | 2024 | 3223 | 2.710 |
Why?
|
Vitamin D Deficiency | 7 | 2024 | 1343 | 1.560 |
Why?
|
Respiratory Sounds | 8 | 2023 | 696 | 1.540 |
Why?
|
Electroconvulsive Therapy | 4 | 2016 | 477 | 1.400 |
Why?
|
Prenatal Exposure Delayed Effects | 6 | 2022 | 2408 | 1.310 |
Why?
|
Pregnancy | 36 | 2023 | 29144 | 0.930 |
Why?
|
Vitamins | 11 | 2024 | 1622 | 0.920 |
Why?
|
Maternal Exposure | 3 | 2020 | 961 | 0.890 |
Why?
|
Pregnancy Trimester, First | 4 | 2020 | 853 | 0.840 |
Why?
|
Premature Birth | 3 | 2020 | 1721 | 0.710 |
Why?
|
Neuromuscular Depolarizing Agents | 2 | 2016 | 45 | 0.670 |
Why?
|
Androstanols | 2 | 2016 | 47 | 0.670 |
Why?
|
Succinylcholine | 2 | 2016 | 67 | 0.670 |
Why?
|
Dietary Supplements | 9 | 2023 | 3297 | 0.670 |
Why?
|
Pregnancy Complications | 3 | 2023 | 2861 | 0.660 |
Why?
|
Neuromuscular Nondepolarizing Agents | 2 | 2016 | 147 | 0.620 |
Why?
|
Diabetes, Gestational | 2 | 2023 | 1184 | 0.570 |
Why?
|
Placenta | 3 | 2020 | 1698 | 0.570 |
Why?
|
Fetal Blood | 2 | 2023 | 1318 | 0.550 |
Why?
|
Cytochrome P-450 CYP2D6 | 1 | 2015 | 106 | 0.520 |
Why?
|
Eczema | 3 | 2022 | 231 | 0.490 |
Why?
|
Pregnancy Trimester, Third | 1 | 2016 | 571 | 0.480 |
Why?
|
NFATC Transcription Factors | 3 | 2020 | 381 | 0.430 |
Why?
|
Anesthesia, Intravenous | 1 | 2013 | 130 | 0.430 |
Why?
|
Antibiotics, Antitubercular | 1 | 2013 | 104 | 0.430 |
Why?
|
Disease Susceptibility | 2 | 2019 | 1782 | 0.430 |
Why?
|
Respiratory Aspiration | 1 | 2013 | 81 | 0.420 |
Why?
|
Gestational Age | 5 | 2023 | 3493 | 0.420 |
Why?
|
Pharyngeal Diseases | 1 | 2013 | 133 | 0.420 |
Why?
|
Cholecalciferol | 1 | 2017 | 537 | 0.420 |
Why?
|
Developmental Disabilities | 1 | 2020 | 1456 | 0.400 |
Why?
|
Neuromuscular Blockade | 1 | 2013 | 146 | 0.400 |
Why?
|
Rifampin | 1 | 2013 | 315 | 0.390 |
Why?
|
Pharmacogenetics | 1 | 2015 | 675 | 0.390 |
Why?
|
Immunomodulation | 1 | 2015 | 541 | 0.380 |
Why?
|
Pharynx | 1 | 2013 | 413 | 0.380 |
Why?
|
Infant, Premature | 1 | 2020 | 2044 | 0.380 |
Why?
|
Neuromuscular Blocking Agents | 1 | 2011 | 130 | 0.370 |
Why?
|
Muscle Weakness | 1 | 2013 | 413 | 0.370 |
Why?
|
Female | 42 | 2023 | 380194 | 0.320 |
Why?
|
Infant, Newborn | 8 | 2023 | 25625 | 0.310 |
Why?
|
Child, Preschool | 14 | 2023 | 41006 | 0.300 |
Why?
|
MicroRNAs | 1 | 2023 | 3752 | 0.300 |
Why?
|
Hypotension | 1 | 2013 | 884 | 0.290 |
Why?
|
Propofol | 1 | 2013 | 629 | 0.290 |
Why?
|
Double-Blind Method | 5 | 2020 | 12026 | 0.270 |
Why?
|
Hypersensitivity | 1 | 2015 | 1102 | 0.270 |
Why?
|
Humans | 51 | 2024 | 744343 | 0.250 |
Why?
|
Antidepressive Agents | 1 | 2015 | 2838 | 0.230 |
Why?
|
Anesthesiology | 1 | 2013 | 1060 | 0.210 |
Why?
|
Calcifediol | 1 | 2023 | 166 | 0.210 |
Why?
|
Respiration, Artificial | 1 | 2013 | 2569 | 0.210 |
Why?
|
Adult | 20 | 2020 | 214055 | 0.200 |
Why?
|
Lung | 4 | 2022 | 9856 | 0.200 |
Why?
|
Cotinine | 2 | 2022 | 206 | 0.200 |
Why?
|
Young Adult | 11 | 2020 | 56430 | 0.190 |
Why?
|
Smoking | 1 | 2017 | 8987 | 0.190 |
Why?
|
Interleukin-8 | 1 | 2023 | 690 | 0.180 |
Why?
|
Child | 15 | 2023 | 77709 | 0.180 |
Why?
|
Hypersensitivity, Immediate | 1 | 2022 | 337 | 0.170 |
Why?
|
Pregnancy Trimesters | 1 | 2020 | 192 | 0.170 |
Why?
|
Male | 19 | 2023 | 350118 | 0.170 |
Why?
|
Chorioamnionitis | 1 | 2020 | 155 | 0.170 |
Why?
|
Cell-Derived Microparticles | 1 | 2020 | 168 | 0.170 |
Why?
|
Airway Resistance | 1 | 2020 | 404 | 0.160 |
Why?
|
Carbamazepine | 1 | 2019 | 229 | 0.160 |
Why?
|
Body Mass Index | 4 | 2020 | 12720 | 0.160 |
Why?
|
Depression, Postpartum | 1 | 2022 | 340 | 0.150 |
Why?
|
Pregnancy Trimester, Second | 1 | 2020 | 732 | 0.150 |
Why?
|
Problem Solving | 1 | 2020 | 440 | 0.150 |
Why?
|
Maternal Age | 1 | 2020 | 802 | 0.150 |
Why?
|
Placebo Effect | 1 | 2020 | 502 | 0.140 |
Why?
|
Case-Control Studies | 7 | 2020 | 21746 | 0.140 |
Why?
|
Chemokines | 1 | 2020 | 970 | 0.140 |
Why?
|
Fentanyl | 1 | 2019 | 410 | 0.140 |
Why?
|
Interleukin-9 | 1 | 2016 | 63 | 0.140 |
Why?
|
Fish Oils | 1 | 2019 | 470 | 0.130 |
Why?
|
Mental Disorders | 1 | 2015 | 6600 | 0.130 |
Why?
|
Incidence | 5 | 2020 | 20947 | 0.120 |
Why?
|
C-Reactive Protein | 2 | 2023 | 3778 | 0.120 |
Why?
|
Prospective Studies | 5 | 2022 | 53288 | 0.120 |
Why?
|
Genetic Predisposition to Disease | 4 | 2021 | 17446 | 0.120 |
Why?
|
Data Collection | 1 | 2023 | 3341 | 0.110 |
Why?
|
Drug Interactions | 2 | 2019 | 1460 | 0.110 |
Why?
|
Single-Blind Method | 1 | 2016 | 1590 | 0.110 |
Why?
|
Gene Regulatory Networks | 2 | 2018 | 1708 | 0.110 |
Why?
|
Prenatal Care | 1 | 2020 | 1092 | 0.110 |
Why?
|
Food Hypersensitivity | 1 | 2019 | 622 | 0.110 |
Why?
|
Pneumonia | 1 | 2024 | 2133 | 0.100 |
Why?
|
Risk Factors | 5 | 2020 | 72290 | 0.100 |
Why?
|
Vecuronium Bromide | 1 | 2011 | 33 | 0.100 |
Why?
|
gamma-Cyclodextrins | 1 | 2011 | 17 | 0.100 |
Why?
|
Atracurium | 1 | 2011 | 52 | 0.100 |
Why?
|
Convulsants | 1 | 2011 | 70 | 0.100 |
Why?
|
Muscle Contraction | 1 | 2016 | 1240 | 0.100 |
Why?
|
Paralysis | 1 | 2013 | 247 | 0.100 |
Why?
|
International Classification of Diseases | 1 | 2016 | 867 | 0.100 |
Why?
|
Cross-Over Studies | 1 | 2016 | 2029 | 0.100 |
Why?
|
Medical Records | 1 | 2016 | 1413 | 0.090 |
Why?
|
Metabolome | 1 | 2017 | 895 | 0.090 |
Why?
|
Odds Ratio | 2 | 2020 | 9849 | 0.090 |
Why?
|
Depressive Disorder | 2 | 2015 | 3748 | 0.090 |
Why?
|
Infant | 4 | 2021 | 35136 | 0.090 |
Why?
|
Isoquinolines | 1 | 2011 | 367 | 0.090 |
Why?
|
DNA Methylation | 1 | 2023 | 4286 | 0.090 |
Why?
|
Magnesium | 1 | 2013 | 813 | 0.090 |
Why?
|
Delivery, Obstetric | 1 | 2016 | 906 | 0.080 |
Why?
|
Cohort Studies | 3 | 2020 | 40561 | 0.080 |
Why?
|
Anticonvulsants | 1 | 2019 | 1916 | 0.080 |
Why?
|
Recurrence | 1 | 2020 | 8340 | 0.080 |
Why?
|
Cytokines | 1 | 2023 | 7322 | 0.080 |
Why?
|
RNA, Messenger | 1 | 2023 | 13033 | 0.080 |
Why?
|
Risk | 1 | 2020 | 9687 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 1 | 2019 | 6538 | 0.080 |
Why?
|
Muscles | 1 | 2013 | 1614 | 0.080 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2019 | 10943 | 0.080 |
Why?
|
Aspirin | 1 | 2020 | 3282 | 0.080 |
Why?
|
Immunity, Innate | 1 | 2019 | 2958 | 0.080 |
Why?
|
Linear Models | 1 | 2017 | 5952 | 0.070 |
Why?
|
Family | 1 | 2017 | 3147 | 0.070 |
Why?
|
Vascular Diseases | 1 | 2014 | 1161 | 0.070 |
Why?
|
Carrier Proteins | 1 | 2019 | 5021 | 0.070 |
Why?
|
Polymorphism, Single Nucleotide | 3 | 2021 | 15519 | 0.070 |
Why?
|
Communication | 1 | 2019 | 3749 | 0.070 |
Why?
|
Phenotype | 3 | 2020 | 16365 | 0.060 |
Why?
|
DNA | 1 | 2018 | 7301 | 0.060 |
Why?
|
Organ Transplantation | 1 | 2014 | 1139 | 0.060 |
Why?
|
Monitoring, Physiologic | 1 | 2011 | 1738 | 0.060 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 9438 | 0.060 |
Why?
|
Patient Discharge | 1 | 2016 | 3313 | 0.060 |
Why?
|
Liver Transplantation | 1 | 2014 | 2119 | 0.060 |
Why?
|
Aged | 5 | 2019 | 163280 | 0.060 |
Why?
|
Leukocytes, Mononuclear | 2 | 2020 | 1836 | 0.060 |
Why?
|
Genome-Wide Association Study | 2 | 2020 | 12261 | 0.050 |
Why?
|
Europe | 2 | 2020 | 3339 | 0.050 |
Why?
|
Analgesics, Opioid | 1 | 2019 | 3674 | 0.050 |
Why?
|
Blood Pressure | 1 | 2018 | 8554 | 0.050 |
Why?
|
Mass Spectrometry | 2 | 2020 | 2203 | 0.050 |
Why?
|
Transcription, Genetic | 1 | 2016 | 7722 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2019 | 9959 | 0.050 |
Why?
|
Age Factors | 1 | 2019 | 18370 | 0.050 |
Why?
|
Middle Aged | 5 | 2019 | 213383 | 0.050 |
Why?
|
Multivariate Analysis | 1 | 2015 | 12245 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2014 | 4149 | 0.050 |
Why?
|
Aged, 80 and over | 2 | 2016 | 57776 | 0.050 |
Why?
|
Logistic Models | 1 | 2015 | 13408 | 0.050 |
Why?
|
Critical Illness | 1 | 2013 | 2670 | 0.050 |
Why?
|
Vitamin D-Binding Protein | 1 | 2021 | 129 | 0.040 |
Why?
|
Intensive Care Units | 1 | 2013 | 3679 | 0.040 |
Why?
|
Treatment Outcome | 3 | 2016 | 63114 | 0.040 |
Why?
|
Adolescent | 2 | 2019 | 85781 | 0.040 |
Why?
|
Severity of Illness Index | 1 | 2017 | 15540 | 0.040 |
Why?
|
Th2 Cells | 1 | 2024 | 1061 | 0.040 |
Why?
|
Seizures | 1 | 2011 | 2859 | 0.040 |
Why?
|
Intention to Treat Analysis | 1 | 2020 | 426 | 0.040 |
Why?
|
Receptors, Calcitriol | 1 | 2021 | 350 | 0.040 |
Why?
|
Prognosis | 1 | 2019 | 29063 | 0.040 |
Why?
|
Mucus | 1 | 2019 | 321 | 0.040 |
Why?
|
Half-Life | 1 | 2019 | 661 | 0.040 |
Why?
|
Prevalence | 1 | 2015 | 15226 | 0.040 |
Why?
|
Respiratory Hypersensitivity | 1 | 2019 | 274 | 0.040 |
Why?
|
Inflammation | 3 | 2024 | 10638 | 0.040 |
Why?
|
Gene Expression Regulation | 1 | 2016 | 12072 | 0.040 |
Why?
|
Tryptophan | 1 | 2019 | 478 | 0.040 |
Why?
|
Muscle, Skeletal | 1 | 2013 | 4931 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2013 | 15076 | 0.040 |
Why?
|
T-Box Domain Proteins | 1 | 2019 | 471 | 0.040 |
Why?
|
Interleukin-2 | 1 | 2024 | 1904 | 0.040 |
Why?
|
Spirometry | 1 | 2020 | 864 | 0.040 |
Why?
|
Risk Assessment | 1 | 2018 | 23338 | 0.040 |
Why?
|
Follow-Up Studies | 2 | 2020 | 39050 | 0.030 |
Why?
|
Amines | 1 | 2017 | 276 | 0.030 |
Why?
|
Michigan | 1 | 2016 | 350 | 0.030 |
Why?
|
Eosinophils | 1 | 2020 | 955 | 0.030 |
Why?
|
Chromatography, Liquid | 1 | 2019 | 976 | 0.030 |
Why?
|
Genotype | 2 | 2021 | 12951 | 0.030 |
Why?
|
Tissue Distribution | 1 | 2019 | 2327 | 0.030 |
Why?
|
Area Under Curve | 1 | 2019 | 1654 | 0.030 |
Why?
|
Allergens | 1 | 2021 | 1320 | 0.030 |
Why?
|
Brain | 1 | 2020 | 26385 | 0.030 |
Why?
|
Metabolic Networks and Pathways | 1 | 2017 | 783 | 0.030 |
Why?
|
Postoperative Complications | 1 | 2014 | 15295 | 0.030 |
Why?
|
Lymphocytes | 1 | 2019 | 2617 | 0.020 |
Why?
|
Time Factors | 1 | 2013 | 40075 | 0.020 |
Why?
|
Morbidity | 1 | 2016 | 1769 | 0.020 |
Why?
|
Fetal Development | 1 | 2016 | 767 | 0.020 |
Why?
|
Veins | 1 | 2014 | 770 | 0.020 |
Why?
|
Trans-Activators | 1 | 2020 | 2924 | 0.020 |
Why?
|
Arteries | 1 | 2014 | 1119 | 0.020 |
Why?
|
Fatty Acids | 1 | 2017 | 1809 | 0.020 |
Why?
|
Steroids | 1 | 2014 | 930 | 0.020 |
Why?
|
Metabolomics | 1 | 2017 | 1484 | 0.020 |
Why?
|
Immune System | 1 | 2014 | 805 | 0.020 |
Why?
|
Inflammation Mediators | 1 | 2017 | 1889 | 0.020 |
Why?
|
History, 21st Century | 1 | 2014 | 1534 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2023 | 7913 | 0.020 |
Why?
|
United States | 3 | 2020 | 69872 | 0.020 |
Why?
|
Proteomics | 1 | 2020 | 3638 | 0.020 |
Why?
|
History, 20th Century | 1 | 2014 | 2740 | 0.020 |
Why?
|
Immune Tolerance | 1 | 2014 | 2258 | 0.020 |
Why?
|
Proteins | 1 | 2020 | 6103 | 0.020 |
Why?
|
Mice | 2 | 2024 | 81183 | 0.020 |
Why?
|
Retrospective Studies | 1 | 2013 | 77449 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2019 | 14557 | 0.020 |
Why?
|
Massachusetts | 1 | 2016 | 8663 | 0.010 |
Why?
|
T-Lymphocytes | 1 | 2020 | 10180 | 0.010 |
Why?
|
Depression | 1 | 2022 | 7766 | 0.010 |
Why?
|
Hematopoietic Stem Cells | 1 | 2014 | 3386 | 0.010 |
Why?
|
Graft Rejection | 1 | 2014 | 4397 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18029 | 0.010 |
Why?
|
Hypertension | 1 | 2020 | 8480 | 0.010 |
Why?
|
Animals | 2 | 2024 | 168757 | 0.010 |
Why?
|
Pediatrics | 1 | 2014 | 3475 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2016 | 19905 | 0.010 |
Why?
|
Apoptosis | 1 | 2014 | 9727 | 0.010 |
Why?
|